Fri Oct 31 21:19:22 SGT 2014  
PEP
HIV
    PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus), Belize - HIV Prevention Treatment
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus), Belize - HIV Prevention Treatment

Summary

PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus), Belize - HIV Prevention Treatment @pephiv_com: Within 3 days of unprotected sex, stop HIV infection with HIV PEP (post-exposure prophylaxis) treatment, Belize - Private and confidential service.

Keywords: PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus) Belize, Belize PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus), PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus).

Description

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
HIV STD TESTING TREATMENT™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: PEP (Post-Exposure Prophylaxis) HIV (Human Immunodeficiency Virus), Belize - HIV Prevention Treatment
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Budget airlines based in Singapore:

Budget airlines operating in Singapore:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

Location reference


Latest News

Futility of CD4+ monitoring in HIV-1 patients with CD4+ cell count above 350 cells/μl on suppressive antiretroviral therapy
Fri, 31 Oct 2014 01:24:12 +0100 | AIDS
No abstract available (Source: AIDS)

Maternal HIV disclosure to young HIV-uninfected children: an evaluation of a family-centred intervention in South Africa: Erratum
Fri, 31 Oct 2014 01:24:12 +0100 | AIDS
No abstract available (Source: AIDS)

Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or ‘blips’ in HIV-1 subtype C
Fri, 31 Oct 2014 01:24:11 +0100 | AIDS
No abstract available (Source: AIDS)

A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops
Fri, 31 Oct 2014 01:24:11 +0100 | AIDS
No abstract available (Source: AIDS)

Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients
Fri, 31 Oct 2014 01:24:10 +0100 | AIDS
No abstract available (Source: AIDS)

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood
Fri, 31 Oct 2014 01:24:09 +0100 | AIDS
Insufficient HIV drug levels in lymph nodes have been linked to viral persistence. To overcome lymphatic drug insufficiency, we developed and evaluated in primates a lipid-drug nanoparticle containing lopinavir, ritonavir, and tenofovir. These nanoparticles produced over 50-fold higher intracellular lopinavir, ritonavir and tenofovir concentrations in lymph nodes compared to free drug. Plasma and intracellular drug levels in blood were enhanced and sustained for 7 days after a single subcutaneous dose, exceeding that achievable with current oral therapy. (Source: AIDS)

Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients
Fri, 31 Oct 2014 01:24:09 +0100 | AIDS
This retrospective study was designed to assess statin effects on T-cell activation from HIV-infected individuals. Peripheral blood mononuclear cells from antiretroviral therapy suppressed HIV-infected individuals receiving atorvastatin or pravastatin were evaluated for T-cell activation, exhaustion and function. Atorvastatin was associated with a significant reduction in CD8 T-cell activation (HLA-DR, CD38/HLA-DR) and exhaustion (TIM-3, TIM-3/PD-1) whereas pravastatin had no effect. In contrast, pravastatin increased antigen specific interferon γ production. These results suggest a differential effect of statins on immune activation and function. (Source: AIDS)

Antiretroviral nanoparticles: the future is now
Fri, 31 Oct 2014 01:24:08 +0100 | AIDS
No abstract available (Source: AIDS)

Selective acquisition of G190S in HIV-1 subtype A from Russia leading to efavirenz and nevirapine treatment failure
Fri, 31 Oct 2014 01:24:07 +0100 | AIDS
No abstract available (Source: AIDS)

Complications of cesarean deliveries among HIV-infected women in the United States
Fri, 31 Oct 2014 01:24:06 +0100 | AIDS
Conclusion:In the United States, rates of cesarean delivery complications decreased from 1995 to 2011. However, rates of infection, surgical trauma, hospital deaths, and prolonged hospitalization are still higher among HIV-infected women. Clinicians should remain alert to this persistently increased risk of cesarean delivery complications among HIV-infected women. (Source: AIDS)